Abstract: Several methods of supporting respiratory function of a patient before, during and/or after a medical procedure are disclosed. In certain arrangements, supporting respiratory function while a patient is under general anaesthesia can include providing a high gas flow a high gas flow that is greater than 15 L/min while the patient is under general anaesthesia.

Abstract: In an example, a method of controlling power distribution in a powered furniture system including a first article of powered furniture having a first controller and a first number of power outlets and a second article of powered furniture having a second number of power outlets and a second controller can include determining a first total number of power outlets in the system, wherein the first total number of power outlets includes at least the first number of power outlets of the first article of powered furniture. The method can include controlling application of power to the first number of power outlets associated with the first article of powered furniture using the determined first total number of power outlets in the system, and transmitting the first total number of power outlets to a second controller of a second article of powered furniture having a second number of power outlets.

Abstract: A load coupling device for a power train including: a rotatable shaft; a first flange on a first end of the shaft, wherein the first flange is adapted to couple to a first rotating shaft of at a torque producing turbine or a torque driven electrical generator; a second flange on an opposite end of the shaft, wherein the shaft is adapted to couple to a second rotating shaft of the other of the turbine and the generator, and an annular ring extending radially outward from the first flange, wherein the mass of the annular ring is selected to shift a torsional natural frequency of the power train away from an operational condition of the power train. Trim masses may be added to make fine adjustments to the torsional natural frequency of the power train.

Abstract: The invention disclosed herein is directed to compounds of Formula I [Formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers.

Abstract: The invention disclosed herein is directed to compounds of Formula I [Formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers.

Abstract: A system of calculating a payload weight, the system including: a first sensor configured to assist in determining an actuator load associated with a ram, the ram being connected to a lifting member; and a calibration module configured to retrieve a calibration factor based on movement of the ram, the calibration factor being applied to the actuator load to thereby provide an adjusted actuator load; wherein the payload weight is calculated based on the adjusted actuator load.

Abstract: Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.

Abstract: A system of calculating a payload weight, the system including: a first sensor configured to measure a first load associated with a first member of a lifting machine; a second sensor configured to measure a second load associated with a second member of the lifting machine; and a calculating device configured to calculate the payload weight being carried by the lifting machine based on the first load and the second load.

Abstract: The invention disclosed herein is directed to compounds of Formula (1a) and (1b) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic? leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (1a) or (1b), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a compound which is a dual antagonist of PPAR? and PPAR?.

Abstract: The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPAR? antagonist.

Abstract: Components of a pocket-sprung-mattress sub-assembly having individual metal springs retained within a matrix of fabric pockets are separated. A rotatable tearing drum 405 is driven by a drive motor 406. Tearing devices 407 are arranged to pull metal springs from a pocket-sprung-mattress sub-assembly during the rotation of the tearing drum 405. A feeding assembly 408 compressors an end portion of the mattress sub-assembly and moves this end portion continually to bring an end of the mattress sub-assembly into contact with the rotating tearing devices 407.

Abstract: The invention disclosed herein is directed to compounds of Formula I [Formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers.

Abstract: The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPAR? antagonist.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Load couplings, power trains, and methods for adjusting torsional natural frequencies of power trains are provided. In one embodiment, a load coupling includes a first flange, a second flange, and a shaft extending between the first flange and the second flange. The load coupling further includes an annular ring extending radially outward from one of the first flange, the second flange, or the shaft, the annular ring including a plurality of bore holes defined therein, each of the plurality of bore holes including a first opening. The load coupling further includes a first cap connected within one of the plurality of bore holes proximate the first opening, the first cap deformable such that an interference fit is created with the one of the plurality of bore holes.

Abstract: The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPAR? antagonist.

Abstract: In a marine power distribution and propulsion system with a medium voltage distribution busbar (MVAC1) and a low voltage distribution busbar (LVAC1) then a rectifier (SC) is controlled, optionally to provide active filtering and static compensation benefits. A common power supply system incorporating ac generators (G1-G4) supplies power to the medium and low voltage distribution busbars. The rectifier (SC) is connected to the medium voltage distribution busbar (MVAC1). A controller (Co) uses feedback signals indicative of electrical quantities of the distribution voltages carried by both the medium voltage and low voltage distribution busbars (MVAC1, LVAC1) to control the rectifier (SC) to regulate electrical quantities at the ac terminals of the rectifier (SC) in order to achieve desired electrical quantities of the distribution voltage carried by the low voltage distribution busbar (LVAC1).

Abstract: The invention disclosed herein is directed to compounds of Formula (1a) and (1b) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic? leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (1a) or (1b), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a compound which is a dual antagonist of PPAR? and PPAR?.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPAR? antagonist.